The U.S. Food and Drug Administration (FDA) on Thursday granted Breakthrough Therapy designation to Eli Lilly and Co.’s (NYSE:LLY) olomorasib, in combination with Merck & Co. Inc.’s (NYSE:MRK) anti-PD ...

Have you ever found yourself juggling multiple projects, only to realize that your team’s resources are stretched too thin or misaligned? In the fast-paced world of project management, resource ...

Akeso, Inc., a leading biopharmaceutical company announced that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab ...

Football is the ultimate team game. A 53-man roster allows room for the most specifically gifted athletes to play a role, no matter how obscure. The Seattle Seahawks may have found one player who is ...

Peluntamig targets DLL3 and CD47, potentially enhancing immune recognition and attack on cancer cells. The SKYBRIDGE study is a phase 1/2 trial assessing peluntamig's safety and efficacy in ...

At 3 years, Opdivo plus Yervoy led to an overall survival rate of 38% in patients with unresectable or metastatic hepatocellular carcinoma, compared to 24% with lenvatinib or sorafenib monotherapy.

TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or ...

With advanced vacuuming, deep-scrub mopping, and a self-cleaning dock, this all-in-one robot keeps your floors spotless with minimal effort This article contains affiliate links from our advertisers.

"Welcome to GamingWithKev – epic gaming, crazy challenges, and nonstop fun. Follow along on Gaming Legends for more!" Barack Obama responds to Donald Trump's Russia "treason" threats US military ...

GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli (dostarlimab) combination in treating first-line advanced ovarian cancer met its ...